TGFB1 and neoplasm: Targeting inhibitory factors within the TME, knockout of TGF-β R2 renders CAR-NK cells resistant to TGF-β–driven immunosuppression [53], producing a 2.3-fold increase in tumor infiltration and sustaining IFN-γ secretion by 50% in pancreatic cancer xenograft models (n = 8).